[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:recurrent-transformed-b-cell-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Recurrent Transformed B-Cell Non-Hodgkin Lymphoma",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07365306","Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[11],"Phase 2","RECRUITING","2026-08-26T02:16:14.341106Z","2026-05-05T02:43:27.484467Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06238648","Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",[11],"2026-08-26T02:16:26.411851Z","2026-05-05T02:43:27.434210Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT06015880","Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[25],"Phase 1","2026-08-26T02:16:27.227548Z","2026-05-05T02:43:26.961325Z",[],[]]